MAAT Stock Overview
A clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MaaT Pharma SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.24 |
| 52 Week High | €9.90 |
| 52 Week Low | €6.30 |
| Beta | 0.19 |
| 11 Month Change | 13.19% |
| 3 Month Change | 17.38% |
| 1 Year Change | 12.88% |
| 33 Year Change | -38.05% |
| 5 Year Change | n/a |
| Change since IPO | -40.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAAT | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 9.6% | -7.7% | -0.3% |
| 1Y | 12.9% | -26.4% | -3.5% |
Return vs Industry: MAAT exceeded the French Biotechs industry which returned -26.5% over the past year.
Return vs Market: MAAT exceeded the French Market which returned -2.5% over the past year.
Price Volatility
| MAAT volatility | |
|---|---|
| MAAT Average Weekly Movement | 4.1% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: MAAT has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: MAAT's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 54 | Herve Affagard | www.maatpharma.com |
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
MaaT Pharma SA Fundamentals Summary
| MAAT fundamental statistics | |
|---|---|
| Market cap | €115.52m |
| Earnings (TTM) | -€24.14m |
| Revenue (TTM) | €2.57m |
44.6x
P/S Ratio-4.8x
P/E RatioIs MAAT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAAT income statement (TTM) | |
|---|---|
| Revenue | €2.57m |
| Cost of Revenue | €1.13m |
| Gross Profit | €1.44m |
| Other Expenses | €25.58m |
| Earnings | -€24.14m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.73 |
| Gross Margin | 56.01% |
| Net Profit Margin | -938.86% |
| Debt/Equity Ratio | 45.0% |
How did MAAT perform over the long term?
See historical performance and comparison